Use this link to cite:
https://hdl.handle.net/2183/45715 Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study
Loading...
Identifiers
Publication date
Authors
Cisneros, José Miguel
Rodríguez-Baño, Jesús
Fernández-Cuenca, Felipe
Ribera, Anna
Vila, Jordi
Pascual, Álvaro
Martínez-Martínez, Luis
Pachón, Jerónimo
Advisors
Other responsabilities
Journal Title
Bibliographic citation
Cisneros JM, Rodríguez-Baño J, Fernández-Cuenca F, Ribera A, Vila J, Pascual A, Martínez-Martínez L, Bou G, Pachón J; Spanish Group for Nosocomial Infection (GEIH) for the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect. 2005 Nov;11(11):874-9.
Type of academic work
Academic degree
Abstract
[Abstract] Potential risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii were investigated in a cohort study in 25 Spanish hospitals. The clonal relationship among isolates was determined by pulsed-field gel electrophoresis (PFGE). In total, A. baumannii was isolated from 203 patients, with imipenem-resistant (MIC(90) 128 mg/L) isolates being obtained from 88 patients (43%), and imipenem-susceptible isolates from 115 patients (57%). A wide clonal distribution was observed among the imipenem-resistant isolates, but spread of the same clone among centres was not demonstrated. The results indicated that imipenem-resistant A. baumannii is a widely distributed nosocomial pathogen in Spain and reaches an alarming frequency in some centres. Independent risk-factors for the acquisition of imipenem-resistant A. baumannii were a hospital size of >500 beds (multivariate OR, 6.5; 95% CI, 1.8--23), previous antimicrobial treatment (multivariate OR, 4.3; 95% CI, 1.6--11), a urinary catheter (multivariate OR, 2.7; 95% CI, 1.1--6.7) and surgery (multivariate OR, 2; 95% CI, 1.07--3.8).
Description
Editor version
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International







